Preliminary Results Display Full Tumor Eradication in Non-surgical Breast Cancer Patients Using IceCure's ProSense® Cryoablation Therapy
Overview
- Company: IceCure Medical Ltd.
- Indication: Early-Stage Breast Cancer
- Drug/Treatment: ProSense® System
- Trial Phase: Not applicable
- NCT ID: Not available
Study Summary
In a groundbreaking study led by Dr. Federica di Naro at Azienda Ospedaliero-Universitaria Careggi, IceCure Medical Ltd. has announced that its ProSense® Cryoablation System has shown potential to fully eradicate tumors in patients with early-stage breast cancer. The study focused on a cohort of thirty-nine non-surgical candidates due to advanced age, comorbidities, or the refusal of surgery. The patients underwent ultrasound-guided cryoablation with the ProSense® system.
Results
The interim results, unveiled in October 2023, revealed a significant reduction in tumor size at varying intervals post-treatment, with a 100% reduction noted at both six and twelve-month evaluations. Core needle biopsies and contrast enhanced mammography confirmed the absence of residual cancerous cells at one year after treatment.
Company Remarks
CEO of IceCure Medical, Eyal Shamir, expressed satisfaction with these results, suggesting that the ProSense® System offers a minimally invasive and effective treatment option for breast cancer patients. The study outcomes support the company's goal to extend the availability and affordability of this innovative technology worldwide.
Technology At A Glance
The ProSense® Cryoablation System is a minimally invasive approach that utilizes rapid-freezing techniques, induced by liquid nitrogen, to destroy both benign and malignant tumors. With fast recovery times, reduced pain, and lower risk of complications, this system is suitable for office-based treatments and is currently approved in various regions including the U.S., Europe, and China.
Conclusion
IceCure Medical Ltd.'s ProSense® Cryoablation System is bringing non-surgical hope to early-stage breast cancer patients. The company continues to work towards broadening the approvals to increase the system's accessibility and cost-effectiveness.